Regular monitoring of a cancer patient’s health is an essential element of treatment, helping to detect one of the most common and costly side effects such as neutropenia, which reduces immune system function and makes them highly vulnerable to serious infections. Currently, most monitoring is done through hospital out-patient appointments, which can be time-consuming and costly to travel to for patients, plus resource intensive for healthcare providers.
This is where the London healthtech startup Entia comes into the picture. The company removes some of these pressures by providing more care for people outside of the hospital and in the home.
Closes £16M funding
In a recent development, Entia has closed £16 million in a Series A funding round led by BGF (that backed TidalSense and Gaussion) and Parkwalk alongside existing investors. The fresh funding is earmarked for the UK commercial rollout and US regulatory approval of the company’s flagship innovation, Liberty. Notably, it is the most comprehensive remote patient monitoring solution for people undergoing cancer treatment.
‘Providing more care for people outside of hospital is not only beneficial for patients but is highly advantageous for healthcare providers,’ said Dr Toby Basey-Fisher, CEO and Founder of Entia. ‘Such an approach allows us to move routine health assessments out of healthcare centres and also drives a more preventative model of healthcare where problems are identified and addressed early on. This is about enhancing patient care by keeping people on treatment longer, reducing unplanned hospitalisations and ultimately improving survival outcomes.’
Joanna Smart, portfolio lead at BGF commented, ‘We have been consistently impressed by the commitment and enthusiasm of the Entia team to significantly improve remote monitoring solutions for cancer patients. This combined with their scientific acumen has created a uniquely user-friendly means of monitoring vital health information with the dual power to transform quality of life and drive efficiencies for healthcare providers. We look forward to supporting the business on the next phase of their journey.’
Neil Cameron, Investment Director at Parkwalk Advisors said, ‘Our investment in Entia offers a profound opportunity to positively impact the lives of people with cancer. Cancer patient numbers are increasing and we need to embed and capitalise on innovative technologies to ensure our healthcare systems have the resources and capacity to give everyone that needs it the best chance of beating this terrible disease.’
At-home cancer patient care tech
Entia was founded by Dr Toby Basey-Fisher in 2014 in London. It transforms healthcare with revolutionary remote patient monitoring and predictive analytics that offer unique insights into a person’s health during cancer therapy.
Entia has combined novel at-home blood testing technology and digital solutions to deliver personalised insights into cancer patients’ journeys through treatment. Its solution is unique as it monitors neutropenia, one of the most common and costly side effects of cancer treatment. It keeps treatment on track and alert them to potential complications before they can affect a patient’s quality of life.
